Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Folicacid supplementation for the prevention of recurrence of colorectal adenomas: metaanalysis of interventional trials. Conflicting data have emerged from preclinical and clinical studies that examined the relationship between folicacid and the risk of recurrence of colorectal adenomas. To determine precisely that relation, we planned this metaanalysis. We searched literature to identify interventional randomized, placebo-controlled studies where folicacid in specific dose and for specific (...) polyps per patient (P = 0.41). Examination of folicacid dose effect showed that the two studies that have used folicacid as 1 mg/day favored folicacid over placebo with an odds ratio of 0.62 (95% CI; 0.48, 0.80). However, the overall effect for all included studies was not significant [odds ratio = 0.78 (95% CI; 0.49, 1.24; P = 0.30)]. We found significant heterogeneity between trials, moreover, included trials exhibit inconsistency in methodological quality. The present metaanalysis has failed
Folicacid to reduce neonatal mortality from neural tube disorders. Neural tube defects (NTDs) remain an important, preventable cause of mortality and morbidity. High-income countries have reported large reductions in NTDs associated with folicacid supplementation or fortification. The burden of NTDs in low-income countries and the effectiveness of folicacid fortification/supplementation are unclear.To review the evidence for, and estimate the effect of, folicacid fortification (...) /supplementation on neonatal mortality due to NTDs, especially in low-income countries.We conducted systematic reviews, abstracted data meeting inclusion criteria and evaluated evidence quality using adapted Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology. Where appropriate, meta-analyses were performed.Meta-analysis of three randomized controlled trials (RCTs) of folicacid supplementation for women with a previous pregnancy with NTD indicates a 70% [95% confidence
Meta-analysis: folicacid in the chemoprevention of colorectal adenomas and colorectal cancer. Folicacid has been identified as a possible agent for the chemoprevention of colorectal cancer.To assess the effectiveness of folicacid in reducing the recurrence of adenomas (precursors of colorectal cancer) among populations with a history of adenomas and the incidence of colorectal cancer within average-risk populations.Systematic review of randomized controlled trials comparing folicacid alone (...) of three trials in general populations demonstrated no statistically significant effect on the relative risk of colorectal cancer (RR 1.13, P = 0.54). In all three analyses, outcome event rates were higher in individuals receiving folic acid.There is no evidence that folicacid is effective in the chemoprevention of colorectal adenomas or colorectal cancer for any population.
Meta-analysis of folicacid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Experimental models and observational studies suggest that homocysteine-lowering therapy with folicacid (FA) may prevent cardiovascular disease (CVD). However, FA also stimulates cell proliferation and might promote progression of atherosclerosis. Our objectives were to perform a meta-analysis of FA supplementation trials on CVD events and to explore
Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folicacid, blood levels, and breast-feeding A committee assembled by the American Academy of Neurology (AAN) reassessed the evidence related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folicacid and prenatal vitamin K use and the clinical implications of placental and breast-milk transfer of antiepileptic drugs (AEDs). The committee evaluated (...) the available evidence based on a structured literature review and classification of relevant articles. Preconceptional folicacid supplementation is possibly effective in preventing major congenital malformations in the newborns of WWE taking AEDs. There is inadequate evidence to determine if the newborns of WWE taking AEDs have a substantially increased risk of hemorrhagic complications. Primidone and levetiracetam probably transfer into breast milk in clinically important amounts. Valproate
Prevalence of severe congenital heart disease after folicacid fortification of grain products: time trend analysis in Quebec, Canada. To investigate whether the 1998 government policy for mandatory fortification of flour and pasta products with folate was followed by a reduction in the prevalence of severe congenital heart defects.Time trend analysis.Province of Quebec, Canada.Infants born in 1990-2005 identified with severe congenital heart defects (tetralogy of Fallot, endocardial cushion (...) 2083 infants born with severe congenital heart defects, corresponding to an average birth prevalence of 1.57/1000 births. Time trend analysis showed no change in the birth prevalence of severe birth defects in the nine years before fortification (rate ratio 1.01, 95% confidence interval 0.99 to 1.03), while in the seven years after fortification there was a significant 6% decrease per year (0.94, 0.90 to 0.97).Public health measures to increase folicacid intake were followed by a decrease
Folicacid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that all women planning or capable of pregnancy take a multivitamin supplement containing folicacid for the prevention of neural tube defects. This recommendation is an update of the 1996 USPSTF recommendation.The USPSTF reviewed the evidence on folicacid supplementation in women of childbearing age published (...) since the 1996 USPSTF recommendation. The USPSTF did not review the evidence on folicacid food fortification, counseling to increase dietary intake, or screening for neural tube defects.The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 microg) of folicacid. (Grade A recommendation).
Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Neural tube defects (NTDs) are among the most common birth defects in the United States. In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that all women planning a pregnancy or capable of conception take a supplement containing folicacid to reduce the risk for NTDs.To search for new evidence published since 1996 on the benefits (...) and harms of folicacid supplementation for women of childbearing age to prevent neural tube defects in offspring, to inform an updated USPSTF recommendation.MEDLINE and Cochrane Central Register of Controlled Trials searches from January 1995 through December 2008, recent systematic reviews, reference lists of retrieved articles, and expert suggestions.English-language randomized, controlled trials; cohort studies; case-control studies; systematic reviews; and meta-analyses were selected
Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Methotrexate is a folicacid antagonist widely used for the treatment of inflammatory disorders for more than 50 years. Methotrexate is a standard systemic therapy for severe psoriasis and rheumatoid arthritis. Folicacid supplementation has been advocated to limit the toxicity of methotrexate on blood cells, gastrointestinal tract and liver. However (...) , there is still controversy regarding the usefulness of folicacid supplementation.We sought to assess the evidence for the efficacy of folicacid supplementation in patients treated with methotrexate for inflammatory diseases. We also investigated whether folicacid supplementation may decrease the efficacy of methotrexate.Cochrane and MEDLINE databases were systematically searched. Randomized controlled trials in patients treated with methotrexate for rheumatoid arthritis or psoriasis with or without
Practice Parameter update: Managment issues for women with epilepsy - Focus on pregnancy: Vitamin K, folicacid, blood levels, and breastfeeding DOI 10.1212/WNL.0b013e3181a6b325 2009;73;142-149 Published Online before print April 27, 2009 Neurology C. L. Harden, P. B. Pennell, B. S. Koppel, et al. of Neurology and American Epilepsy Society Technology Assessment Subcommittee of the American Academy the Quality Standards Subcommittee and Therapeutics and Vitamin K, folicacid, blood levels (...) , MD J. Hopp, MD T.Y. Ting, MD W.A. Hauser, MD D.Thurman,MD,MPH P.W.Kaplan,MB,FRCP J.N. Robinson, MD J.A. French, MD S. Wiebe, MD A.N. Wilner, MD B. Vazquez, MD L. Holmes, MD A. Krumholz, MD R. Finnell, PhD P.O. Shafer, RN, MN C. Le Guen ABSTRACT Objective:To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folicacid use, prenatal vitamin K use, risk of hemorrhagic disease of the newborn, clinical implications
Management issues for women with epilepsy-focus on pregnancy: vitamin k, folicacid, blood levels, and breastfeeding Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folicacid, blood levels, and breastfeeding | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share July 14, 2009 ; 73 (2) Special (...) Article Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folicacid, blood levels, and breastfeeding Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society C. L. Harden , P. B. Pennell , B. S. Koppel , C. A. Hovinga , B. Gidal , K. J. Meador , J. Hopp , T. Y. Ting , W. A. Hauser , D. Thurman , P. W. Kaplan , J. N
Cancer incidence and mortality after treatment with folicacid and vitamin B12. Recently, concern has been raised about the safety of folicacid, particularly in relation to cancer risk.To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin (...) Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.Oral treatment with folicacid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) and vitamin B(6) (40 mg/d) (n = 1708); folicacid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) (n = 1703); vitamin B(6) alone (40 mg/d) (n = 1705); or placebo (n = 1721).Cancer incidence, cancer mortality, and all-cause mortality.During study treatment
High-dose folicacid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): vitamin K, folicacid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Asse Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): vitamin K, folicacid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics (...) and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): vitamin K, folicacid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ
Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Wolff T, Witkop CT, Miller T, Syed SB Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wolff T, Witkop CT, Miller T, Syed SB. Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 70. 2009 Authors' objectives To update the evidence on folicacid
High-dose folicacid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials. Folicacid supplementation has been shown to be an effective agent for improving endothelial function, a prognostic factor for cardiovascular disease; but its effects on systolic and diastolic blood pressure in hypertensive individuals has been met with mixed results. Therefore, the purpose of this study was to provide (...) a comprehensive meta-analysis of randomized controlled trials to investigate the effect of high-dose folicacid supplementation on blood pressure and endothelial function in hypertensive patients.Twelve randomized controlled trials published between 1970 and December 2007 were identified using Medline and a manual search. All 12 studies used hypertensive subjects who were supplemented with at least 5000 mug/d of folicacid for between 2 and 16 weeks. Three separate meta-analyses were carried out using
Effects and safety of preventive oral iron or iron+folicacid supplementation for women during pregnancy. Intake of supplements containing iron or a combination of iron and folicacid by pregnant women may improve maternal health and pregnancy outcomes. Recently, intermittent supplementation regimens have been proposed as alternatives to daily regimens.To assess the effectiveness and safety of daily and intermittent use of iron or iron+folicacid supplements by pregnant women.We searched (...) the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2009) and contacted relevant organisations for the identification of ongoing and unpublished studies.All randomised or quasi-randomised trials evaluating the effect of supplementation with iron or iron+folicacid during pregnancy.We assessed the methodological quality of trials using the standard Cochrane criteria. Two authors independently assessed which trials to include in the review and one author extracted data.We included 49 trials
Impact of multiple micronutrient versus iron-folicacid supplements on maternal anemia and micronutrient status in pregnancy. Multiple micronutrient supplements could increase hemoglobin and improve micronutrient status of pregnant women more than iron supplements alone or iron with folic acid.To compare the effects of multiple micronutrients with those of iron supplements alone or iron with folicacid, on hemoglobin and micronutrient status of pregnant women.Studies were identified in which (...) pregnant women were randomized to treatment with multiple micronutrients, or with iron with or without folicacid. A pooled analysis was conducted to compare the effects of these supplements on maternal hemoglobin, anemia, and micronutrient status. Effect size was calculated for individual and combined studies, based on mean change from baseline to final measure in the group receiving iron, with or without folicacid, minus the mean change in the group, divided by the pooled standard deviation
Folicacid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Folate deficiency can result in congenital neural tube defects and megaloblastic anaemia. Low folate levels may be due to insufficient dietary intake or inefficient absorption, but impaired metabolic utilization also occurs.Because B12 deficiency can produce a similar anaemia to folate deficiency, there is a risk that folate supplementation can delay the diagnosis of B12 deficiency (...) , which can cause irreversible neurological damage. Folicacid supplements may sometimes therefore include vitamin B12 supplements with simultaneous administration of vitamin B12.Lesser degrees of folate inadequacy are associated with high blood levels of the amino acid homocysteine which has been linked with the risk of arterial disease, dementia and Alzheimer's disease. There is therefore interest in whether dietary supplementation can improve cognitive function in the elderly.However, any apparent